This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
NCT01972841 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 3527
Last updated 2024-10-31
Summary
The purpose of this study was to examine how well two medicines (solifenacin succinate and mirabegron) combined work compared to each medicine alone in the treatment of bladder problems.
Conditions
- Urinary Bladder Overactive
- Urinary Bladder Diseases\Urologic Diseases
- Overactive Bladder
- Urgency Incontinence
Interventions
- DRUG
-
Solifenacin succinate
Oral tablet
- DRUG
-
Mirabegron
Oral tablet
- DRUG
-
Placebo to match solifenacin succinate
Oral tablet
- DRUG
-
Placebo to match mirabegron
Oral tablet
Sponsors & Collaborators
-
Astellas Pharma Europe B.V.
lead INDUSTRY
Principal Investigators
-
Medical Director · Astellas Pharma Europe B.V.
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-11-05
- Primary Completion
- 2015-10-22
- Completion
- 2015-10-22
Countries
- United States
- Argentina
- Australia
- Belgium
- Bulgaria
- Canada
- China
- Colombia
- Czechia
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hong Kong
- Hungary
- Italy
- Latvia
- Lithuania
- Malaysia
- Mexico
- Netherlands
- New Zealand
- Norway
- Peru
- Philippines
- Poland
- Romania
- Russia
- Singapore
- Slovakia
- Slovenia
- South Africa
- South Korea
- Spain
- Sweden
- Taiwan
- Thailand
- Turkey (Türkiye)
- Ukraine
- United Kingdom
Study Locations
More Related Trials
-
A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder
NCT00501267 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients
NCT01745094 ·Status: COMPLETED ·Phase: PHASE4
-
A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder
NCT03566134 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women
NCT03475706 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00688688 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00912964 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder
NCT06479720 ·Status: RECRUITING ·Phase: PHASE4
-
Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes
NCT02540707 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder
NCT03558919 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder
NCT05282069 ·Status: COMPLETED ·Phase: PHASE3
-
MIrabegron With oveRACtive bLadder Symptoms in mEn
NCT02361502 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00662909 ·Status: COMPLETED ·Phase: PHASE3
-
Management of OAB in Female Patients .
NCT06184334 ·Status: COMPLETED ·Phase: NA
-
Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects
NCT02938507 ·Status: COMPLETED ·Phase: PHASE1
-
Sequencing and Combination of Mirabegron and TTNS in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover Trial
NCT05188742 ·Status: UNKNOWN ·Phase: PHASE4
-
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
NCT02216214 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity
NCT06197295 ·Status: RECRUITING ·Phase: PHASE4
-
A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
NCT02138747 ·Status: COMPLETED ·Phase: PHASE4
-
Solifenacin Succinate Versus Tolterodine 4mg Once Daily
NCT00802373 ·Status: COMPLETED ·Phase: PHASE3
-
A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)
NCT02386072 ·Status: COMPLETED
-
A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)
NCT01314872 ·Status: COMPLETED ·Phase: PHASE2
-
Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients
NCT02044510 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)
NCT03594058 ·Status: COMPLETED ·Phase: PHASE2
-
Study of ONO-8577 in Patients With Overactive Bladder
NCT03106623 ·Status: COMPLETED ·Phase: PHASE2
-
Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome
NCT05040984 ·Status: UNKNOWN